Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat, Bortezomib, and Vincristine in Relapsed Pediatric T-Cell ALL/Lymphoma
NCT02518750Phase 2Terminated
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Nov 2016
- Primary completion
- Mar 2018
- Modality
- Modified Peptides, Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat, bortezomib, vincristine sulfate liposome injection in acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), sponsored by St. Jude Children's Research Hospital. Started Nov 2016; status: terminated.
02
Drugs
panobinostatbortezomibvincristine sulfate liposome injection
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02518750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02518750.